SynaptixBio awarded £2m BioMedical Catalyst grant from Innovate UK
The grant will support clinical trials of rare disease therapy for leukodystrophy
Read More
Tag: SynaptixBio
SynaptixBio says NHS diagnostic service for rare diseases could be expanded
A rare disease is defined as a condition that affects fewer than one in 2,000 people
Read More
SynaptixBio receives incurable disease research boost
The Oxford-based biotech company has secured £13.2m to progress world’s vital treatment development
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
